FDA’s Anti-Counterfeit Strategy Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Implications for pharma’s compliance burden may not be too far down the line as agency turns to Risk Communication Advisory Committee for techniques to encourage safe drug purchasing practices.